Targeted therapies in small cell lung cancer: A review

Aidalena Z. Abidin; Marina C. Garassino; Raffaele Califano; Amelie Harle; Fiona Blackhall

doi:10.1177/1758834009356014

Targeted therapies in small cell lung cancer: A review

Aidalena Z. Abidin, Marina C. Garassino, Raffaele Califano, Amelie Harle, Fiona Blackhall

Research output: Contribution to journal › Article › peer-review

Abstract

Small cell lung cancer (SCLC) is an aggressive form of lung cancer that is characterized by a rapid doubling time, early onset of dissemination and high sensitivity to chemotherapy. Despite the potential for cure in patients with limited disease with concurrent chemoradiation and an initial good response to chemotherapy in extensive disease, there is a high chance of disease relapse with an overall poor median survival for both stages. With increasing translational research and a better understanding of the molecular basis of cancer, a number of molecular targets have been identified in various preclinical studies. This review summarizes potentially viable targets and new agents that have been developed and employed in recent, ongoing and future clinical trials to attempt to improve clinical outcomes in this disease. © The Author(s), 2010.

Original language	English
Pages (from-to)	25-37
Number of pages	12
Journal	Therapeutic Advances in Medical Oncology
Volume	2
Issue number	1
DOIs	https://doi.org/10.1177/1758834009356014
Publication status	Published - 2010

Keywords

Angiogenesis inhibitors
Apoptosis promoters
BH3 mimetics
Cell signalling inhibitors
Met inhibitors
Multidrug resistance inhibitors
Small cell lung cancer (SCLC)
Targeted therapies
Vaccines

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/1758834009356014

Cite this

@article{4cc02d295722476da547d9dca8a1f6ff,

title = "Targeted therapies in small cell lung cancer: A review",

abstract = "Small cell lung cancer (SCLC) is an aggressive form of lung cancer that is characterized by a rapid doubling time, early onset of dissemination and high sensitivity to chemotherapy. Despite the potential for cure in patients with limited disease with concurrent chemoradiation and an initial good response to chemotherapy in extensive disease, there is a high chance of disease relapse with an overall poor median survival for both stages. With increasing translational research and a better understanding of the molecular basis of cancer, a number of molecular targets have been identified in various preclinical studies. This review summarizes potentially viable targets and new agents that have been developed and employed in recent, ongoing and future clinical trials to attempt to improve clinical outcomes in this disease. {\textcopyright} The Author(s), 2010.",

keywords = "Angiogenesis inhibitors, Apoptosis promoters, BH3 mimetics, Cell signalling inhibitors, Met inhibitors, Multidrug resistance inhibitors, Small cell lung cancer (SCLC), Targeted therapies, Vaccines",

author = "Abidin, {Aidalena Z.} and Garassino, {Marina C.} and Raffaele Califano and Amelie Harle and Fiona Blackhall",

year = "2010",

doi = "10.1177/1758834009356014",

language = "English",

volume = "2",

pages = "25--37",

journal = "Therapeutic Advances in Medical Oncology",

issn = "1758-8340",

publisher = "SAGE Publications Inc.",

number = "1",

}

TY - JOUR

T1 - Targeted therapies in small cell lung cancer: A review

AU - Abidin, Aidalena Z.

AU - Garassino, Marina C.

AU - Califano, Raffaele

AU - Harle, Amelie

AU - Blackhall, Fiona

PY - 2010

Y1 - 2010

N2 - Small cell lung cancer (SCLC) is an aggressive form of lung cancer that is characterized by a rapid doubling time, early onset of dissemination and high sensitivity to chemotherapy. Despite the potential for cure in patients with limited disease with concurrent chemoradiation and an initial good response to chemotherapy in extensive disease, there is a high chance of disease relapse with an overall poor median survival for both stages. With increasing translational research and a better understanding of the molecular basis of cancer, a number of molecular targets have been identified in various preclinical studies. This review summarizes potentially viable targets and new agents that have been developed and employed in recent, ongoing and future clinical trials to attempt to improve clinical outcomes in this disease. © The Author(s), 2010.

AB - Small cell lung cancer (SCLC) is an aggressive form of lung cancer that is characterized by a rapid doubling time, early onset of dissemination and high sensitivity to chemotherapy. Despite the potential for cure in patients with limited disease with concurrent chemoradiation and an initial good response to chemotherapy in extensive disease, there is a high chance of disease relapse with an overall poor median survival for both stages. With increasing translational research and a better understanding of the molecular basis of cancer, a number of molecular targets have been identified in various preclinical studies. This review summarizes potentially viable targets and new agents that have been developed and employed in recent, ongoing and future clinical trials to attempt to improve clinical outcomes in this disease. © The Author(s), 2010.

KW - Angiogenesis inhibitors

KW - Apoptosis promoters

KW - BH3 mimetics

KW - Cell signalling inhibitors

KW - Met inhibitors

KW - Multidrug resistance inhibitors

KW - Small cell lung cancer (SCLC)

KW - Targeted therapies

KW - Vaccines

U2 - 10.1177/1758834009356014

DO - 10.1177/1758834009356014

M3 - Article

C2 - 21789124

SN - 1758-8340

VL - 2

SP - 25

EP - 37

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

IS - 1

ER -

Targeted therapies in small cell lung cancer: A review

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this